

## human Glucagon-Like Peptide 2 Receptor (GLP2R) Cell Line

Product No.: ES-711-C

Lot No.: 1608212

### Material Provided

Cells: 2 x 1 mL frozen aliquot (ES-711-CV)

Format: ~2.5 x 10<sup>6</sup> cells /mL in freezing medium

### Product Information

Cellular Background: 1321N1

Cell Line Development: Our proprietary bicistronic expression plasmid containing the sequence coding for the human Glucagon-Like Peptide 2 Receptor (GLP2R) was transfected in 1321N1 cells. Geneticin-resistant clones were obtained by limit dilution and compared for receptor expression levels using a radioligand binding assay. The clone with the highest receptor expression level was selected for characterization in binding and functional assays.

DNA Sequence: Identical to coding sequence of GenBank NM\_004246.1, with the exception of two silent mutations located in codon # 170 (GAC becomes GAT, both coding for an Asp) and in codon # 442 (GAA becomes GAG, both coding for a Glu).

Corresponding Protein Sequence: Identical to GenBank NP\_004237.1.

Receptor expression level (B<sub>max</sub>): Saturation binding assays performed with [<sup>125</sup>I]GLP-2 did not allow to determine with confidence the B<sub>max</sub> value.

K<sub>d</sub> for the above radioligand: N/D

Shipping Conditions: Shipped on dry ice. Please ensure dry ice is still present in the package upon receipt or contact customer support.

Storage Conditions: Store in liquid nitrogen (vapor phase) immediately upon receipt.



## Quality Control

The EC<sub>50</sub> for a reference agonist was determined in LANCE® cAMP assay performed on an EnVision® instrument. A mycoplasma test was performed using MycoAlert® (Lonza) mycoplasma detection kit. We certify that these results meet our quality release criteria.

GLP-2 (1-34) [Arg<sup>34</sup>] (human) (EC<sub>50</sub>): 10 pM

Stability: Cells were kept in continuous culture for at least 60 days and showed no decrease of receptor expression level in a saturation binding assay (stable B<sub>max</sub> and K<sub>d</sub>) and no decrease in functional response (EC<sub>50</sub>, E<sub>max</sub> in cAMP assay).

Mycoplasma: This cell line tested negative for mycoplasma.

## Assay Procedures

We have shown for many of our GPCR cell lines that freshly thawed cells respond with the same pharmacology as cultured cells. All of our products validated in this way are available as frozen ready-to-use cells in our catalogue. This demonstrates that cells can be prepared and frozen in advance of a screening campaign simplifying assay logistics.

## Recommended Cell Culture Conditions (1321N1)

- The recommended media catalogue number and supplier reference information are listed in this Product Technical Data Sheet (last page). Media composition is specifically defined for each cell type and receptor expression selection. The use of incorrect media or component substitutions can lead to reduced cell viability, growth issues and/or altered receptor expression.
- Cells undergo major stress upon thawing, and need to adapt to their new environment which may initially affect cell adherence and growth rates. The initial recovery of the cells, and initial doubling time, will vary from laboratory to laboratory, reflecting differences in the origin of culture media and serum, and differences in methodology used within each laboratory.
- For the initial period of cell growth (i.e. until cells have reached Log-phase, typically 4-10 days), we strongly recommend removal of the antibiotics (G418, Zeocin™, Puromycin, Blastidicin, Hygromycin, Penicillin and Streptomycin) from the culture media. Immediately after thawing, cells may be more permeable to antibiotics, and a higher intracellular antibiotic concentration may result as a consequence. Antibiotics should be re-introduced when cells have recovered from the thawing stress.

Growth Medium: DMEM, 10% FBS, 1 mM sodium pyruvate, 0.5 mg/ml Geneticin (receptor expression selection).

Freezing Medium: DMEM, 10% FBS, 1 mM sodium pyruvate with 10% DMSO, without selection agents.

Thawing Cells: Using appropriate personal protective equipment, rapidly place the frozen aliquot in a 37°C water bath (do not submerge) and agitate until its content is thawed completely. Immediately remove from water bath, spray aliquot with 70% ethanol and wipe excess. Under aseptic conditions using a sterile pipette, transfer content to a sterile centrifuge tube containing 10 mL growth medium without antibiotics, pre-warmed at 37°C, and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in 10 mL of pre-warmed growth medium without antibiotics by pipetting up and down to break up any clumps, and transfer to an appropriate culture flask (e.g. T-25, T-75 or T-175, see recommended seeding density below). Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.


Recommended Seeding Density:	Thawing:	30,000 – 35,000 cells/cm <sup>2</sup>
	Log-phase:	19,000 – 23,000 cells/cm <sup>2</sup>

Troubleshooting: Initial doubling time can vary between 18 and 96 hours (Average = 25 hours). If cells are still not adhering after 48 hours or grow very slowly, we recommend maintaining the cells in culture and not replacing the media before 5-6 days (cells secrete factors that can help with adherence and growth). If confluence is still <50% after 5-6 days, it is recommended that you replace the media with fresh media (without antibiotics). Do not passage the cells until they reach 80-90% confluence (Log-phase). If cells have not recovered after 10-12 days, please contact our Technical Support.

Culture Protocol: Under aseptic conditions, cells are grown to 80% confluence (Log-phase) and trypsinized (0.05% trypsin / 0.5 mM EDTA in calcium and magnesium-free PBS). See recommended seeding density for Log-phase above.

Banking Protocol: Cells are grown to 70-80% confluence (Log-phase). Under aseptic conditions, remove medium and rinse the flask with an appropriate volume of calcium and magnesium-free PBS (example 10 mL for T-175). Trypsinize (0.05% trypsin / 0.5 mM EDTA in calcium and magnesium-free PBS) to detach cells (example 5 mL for T-175), let stand 5-10 min at 37°C. Add fresh, room temperature growth medium (without antibiotics) to stop trypsinization and dilute EDTA (example 10 mL for T-175). Transfer cells to a sterile centrifuge tube and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in ice-cold freezing medium by pipetting up and down to break up any clumps. Count cells and rapidly aliquot at the selected cell density (e.g. 2.5 x 10<sup>6</sup> cells/mL) in sterile polypropylene cryovials. Use appropriate material to ensure slow cooling (about -1°C/min) until -70°C. Transfer vials into a liquid nitrogen tank (vapor phase) for storage.

# Typical Product Data -LANCE® cAMP Assay



Agonist	EC <sub>50</sub> (M)
GLP-2 (1-33) (rat)	6.3 x 10 <sup>-11</sup>
GLP2 (1-34) [Arg <sup>34</sup> ] (human)	9.1 x 10 <sup>-11</sup>

Figure 1. Agonist Response in LANCE® cAMP assay

An agonist dose-response experiment was performed in 384-well format using 2,500 cells/well. Cells were incubated for 30-min with the indicated agonist concentrations. Time-resolved fluorescence was measured on an EnVision® instrument. Data from a representative experiment are shown.

## LANCE® *Ultra* cAMP Assay Procedure

Stimulation Buffer: HBSS, 5 mM HEPES, 0.1 % Protease-free BSA, 0.5 mM IBMX, pH 7.4.

Cells/well: For compounds not tested herein we recommend titrating the cells for optimal performance, i.e. 500-3,000 cells per assay point.

cAMP measurements can be performed with the LANCE® *Ultra* cAMP 384 Kit (Revvity # TRF0262), according to the manufacturer instructions. Briefly:

Protocols for a 384-well white Optiplate (total assay volume of 20 µL):

cAMP Standard curve	G <sub>s</sub> Agonist	G <sub>s</sub> Antagonist	G <sub>i</sub> Forskolin titration	G <sub>i</sub> Agonist	G <sub>i</sub> Antagonist
5 µL cAMP Standard	5 µL cell suspension	5 µL cell suspension	5 µL cell suspension	5 µL cell suspension	5 µL cell suspension
5 µL Stimulation Buffer	5 µL Agonist	2.5 µL Antagonist	5 µL Forskolin	2.5 µL Agonist	2.5 µL Antagonist
-	-	2.5 µL Agonist	-	2.5 µL Forskolin	2.5 µL Forskolin/Agonist
Incubate 30 min at room temperature (optional step for cAMP Standard curve)					
5 µL 4X Eu-cAMP Tracer Working Solution					
5 µL 4X ULight-anti-cAMP Working Solution					
Incubate 1 h at room temperature					
Read on an EnVision® instrument. Remove microplate seal prior to reading					

- Cells in mid-log phase, grown in media without antibiotics for 18 hours prior to the experiment, are detached by gentle flushing with PBS-EDTA, recovered by centrifugation and resuspended in stimulation buffer e.g. at the concentration of  $6.0 \times 10^5$  cells/mL (for 3000 cells/well).
- Prepare the 4X Tracer Working Solution by making a 1/50 dilution of the Eu-cAMP stock solution in the cAMP Detection Buffer.
- Prepare an ULight-anti-cAMP Intermediate Solution by making a 1/10 dilution of the ULight-anti-cAMP stock solution in cAMP Detection Buffer. Prepare the 4X ULight-anti-cAMP Working Solution by making a 1/30 dilution of the ULight-anti-cAMP intermediate solution in the cAMP Detection Buffer.

### Notes:

For 96- and 1536-well formats, adjust proportionally the volume of each assay component in order to maintain the volume ratios for the 384-well format. Do not modify the Eu-cAMP and/or the ULight-anti-cAMP concentrations.

## LANCE® cAMP Assay Procedure

Stimulation Buffer: HBSS, 5 mM HEPES, 0.1 % Protease-free BSA, 0.5 mM IBMX, pH 7.4.

Cells/well: 2500. For compounds not tested herein we recommend titrating the cells for optimal performance, i.e. 1000-10,000 cells per assay point.

Antagonist Pre-incubation: Simultaneous addition of antagonists with reference agonist.

Agonist Stimulation: 30 min at room temperature (22°C).

cAMP measurements were performed with the LANCE® cAMP 384 Kit (Revvity # AD0262), according to the manufacturer instructions. Briefly:

1. Compounds (6 µL/well) were dispensed into a 384-well white Optiplate:

	G <sub>αs</sub> and G <sub>αi</sub> assay modes		G <sub>αs</sub> assay mode		G <sub>αi</sub> assay mode	
	Basal	Forskolin	Agonist Assay	Antagonist Assay	Agonist Assay	Antagonist Assay
Buffer	6 µL	-	-	-	-	-
Antagonist	-	-	-	3 µL of 4x final conc.	-	3 µL of 4x final conc.
Agonist	-	-	6 µL of 2x final conc.	3 µL of 4x final conc.	6 µL of 2x final conc. in 2x final FK conc.	3 µL of 4x final conc. in 4x final FK conc.
Forskolin	-	6 µL of 2x final conc.	-	-		

2. Cells in mid-log phase, grown in media without antibiotics for 18 hours prior to the experiment, were detached by gentle flushing with PBS-EDTA, recovered by centrifugation and resuspended in stimulation buffer at the concentration of  $4.2 \times 10^5$  cells/mL.
3. The Alexa Fluor® 647-anti cAMP antibody was added 1/100 (vol/vol) to the cell suspension.
4. 6 µL/well of cell and antibody suspension (2500 cells/well) were dispensed on top of the compounds prepared in the 384 well Optiplate.
5. After incubation for 30 min at room temperature the reaction was stopped by addition of 12 µL of Detection Mix.
6. The plate was incubated for 60 min at room temperature and read on an EnVision®.

Note: Assays can also be miniaturized into 1536-well format.

## References

1. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A. (1999) Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A. 96:1569-1573.
2. Brubaker PL, Drucker DJ. (2002) Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels. 8:179-188.
3. Estall JL, Drucker DJ. (2006) Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des. 12:1731-1750.
4. Yazbeck R, Howarth GS, Abbott CA (2009) Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? Cytokine Growth Factor Rev. 20:175-184.

## Materials and Instrumentation

The following tables provide the references of compounds and reagents used or recommended for the characterization of the human Glucagon-Like Peptide 2 Receptor (GLP2R) ValiScreen® cell line, as well as some advice on how to use these compounds:

Table 1. References of compounds used for functional characterization and binding assays

Name	Provider	Cat no	Working Stock Solution
GLP-2 (1-33) (rat) (H-HADGSFSDEMNTILDNLATRDFINWLIQTKITD-OH Sequence)	Bachem	H-5002	100 µM in PBS + 0.1% protease-free BSA
GLP2 (1-34) [Arg <sup>34</sup> ] (human) (H-HADGSFSDEMNTILDNLAARDFINWLIQTKITDR-OH Sequence)	Bachem	H-4766	100 µM in PBS + 0.1% protease-free BSA
[ <sup>125</sup> I]GLP-2	Revvity	NEX390	N/A

Table 2. References of cell culture media and assay buffers

Name	Provider	Cat no
HAM's F-12	Hyclone	SH30026.02
DMEM	Hyclone	SH30022.02
Advanced DMEM/F12 (serotonin receptors)	Invitrogen	12634-010
EMEM	BioWitthaker	06-174G
EX-CELL DHFR <sup>+</sup> media (DHFR deficient cell lines)	Sigma	C8862
FBS	Wisent	80150
FBS dialyzed	Wisent	80950
G418 (geneticin)	Wisent	400-130-IG
Zeocin	Invitrogen	R25005
Blasticidin	invitrogen	R210-01
Puromycin	Wisent	400-160-EM
Standard HBSS (with CaCl <sub>2</sub> and MgCl <sub>2</sub> )	GIBCO	14025
HEPES	MP Biomedicals, LLC	101926
BSA, Protease-free	Sigma	A-3059
PEI	Sigma	P3143
Trypsin-EDTA	Hyclone	SH30236.02
Sodium Pyruvate	GIBCO	11360
L-Glutamine	GIBCO	25030
NEAA (non-essential amino acids)	GIBCO	11140
Forskolin	Sigma	F6886

This product is not for resale or distribution except by authorized distributors. The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.